194 related articles for article (PubMed ID: 17332241)
1. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma.
Trudel S; Li ZH; Rauw J; Tiedemann RE; Wen XY; Stewart AK
Blood; 2007 Jun; 109(12):5430-8. PubMed ID: 17332241
[TBL] [Abstract][Full Text] [Related]
2. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
[TBL] [Abstract][Full Text] [Related]
3. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P
J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572
[TBL] [Abstract][Full Text] [Related]
4. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
5. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.
Huang S; Okumura K; Sinicrope FA
Clin Cancer Res; 2009 Jan; 15(1):150-9. PubMed ID: 19118042
[TBL] [Abstract][Full Text] [Related]
6. Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim.
Nguyen M; Cencic R; Ertel F; Bernier C; Pelletier J; Roulston A; Silvius JR; Shore GC
BMC Cancer; 2015 Aug; 15():568. PubMed ID: 26231047
[TBL] [Abstract][Full Text] [Related]
7. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
Dasmahapatra G; Lembersky D; Son MP; Patel H; Peterson D; Attkisson E; Fisher RI; Friedberg JW; Dent P; Grant S
Mol Cancer Ther; 2012 May; 11(5):1122-32. PubMed ID: 22411899
[TBL] [Abstract][Full Text] [Related]
8. Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex.
Gomez-Bougie P; Oliver L; Le Gouill S; Bataille R; Amiot M
Oncogene; 2005 Dec; 24(54):8076-9. PubMed ID: 16091744
[TBL] [Abstract][Full Text] [Related]
9. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
Nguyen M; Marcellus RC; Roulston A; Watson M; Serfass L; Murthy Madiraju SR; Goulet D; Viallet J; Bélec L; Billot X; Acoca S; Purisima E; Wiegmans A; Cluse L; Johnstone RW; Beauparlant P; Shore GC
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19512-7. PubMed ID: 18040043
[TBL] [Abstract][Full Text] [Related]
10. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D
Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835
[TBL] [Abstract][Full Text] [Related]
11. Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells.
Pei XY; Dai Y; Felthousen J; Chen S; Takabatake Y; Zhou L; Youssefian LE; Sanderson MW; Bodie WW; Kramer LB; Orlowski RZ; Grant S
PLoS One; 2014; 9(3):e89064. PubMed ID: 24594907
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Blood; 2012 Jun; 119(25):6089-98. PubMed ID: 22446485
[TBL] [Abstract][Full Text] [Related]
13. A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1.
Zhang Z; Song T; Zhang T; Gao J; Wu G; An L; Du G
Int J Cancer; 2011 Apr; 128(7):1724-35. PubMed ID: 20503275
[TBL] [Abstract][Full Text] [Related]
14. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination.
Gómez-Benito M; Marzo I; Anel A; Naval J
Mol Pharmacol; 2005 Jun; 67(6):1991-8. PubMed ID: 15738311
[TBL] [Abstract][Full Text] [Related]
15. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
Pei XY; Dai Y; Grant S
Mol Cancer Ther; 2004 Dec; 3(12):1513-24. PubMed ID: 15634644
[TBL] [Abstract][Full Text] [Related]
16. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells.
Gomez-Bougie P; Bataille R; Amiot M
Eur J Immunol; 2004 Nov; 34(11):3156-64. PubMed ID: 15459900
[TBL] [Abstract][Full Text] [Related]
17. S1, a novel pan-BH3 mimetic, induces apoptosis in Mcl-1-overexpressing cells through Bak.
Song T; Chang X; Zhang Z; Liu Y; Shen X
J Pharmacol Sci; 2012; 119(4):330-40. PubMed ID: 22814102
[TBL] [Abstract][Full Text] [Related]
18. Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis.
Gomez-Bougie P; Halliez M; Moreau P; Pellat-Deceunynck C; Amiot M
Cancer Lett; 2016 Dec; 383(2):204-211. PubMed ID: 27697610
[TBL] [Abstract][Full Text] [Related]
19. Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax.
Jiang CC; Wroblewski D; Yang F; Hersey P; Zhang XD
Neoplasia; 2009 Sep; 11(9):945-55. PubMed ID: 19724688
[TBL] [Abstract][Full Text] [Related]
20. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
